PMH24 Cost of Long-Acting Risperidone Injection Versus Long-Acting Paliperidone Palmitate in Patients With Schizophrenia in Russia

Abstract

emergency room visits, and quality-adjusted life-years. RESULTS: PP-LAI was dominant. It cost €10,169/patient; outcomes included 330.1 days in remission, 25% were hospitalized, 12% visited emergency rooms and 0.845 QALY. OLZ-LAI costs were €11,589; patients experienced 326.8 remission days and 0.844 QALY; 27% were hospitalized and 14% visited emergency rooms. RIS-LAI costs were €12,091; patients experienced 323.8 remission days and 0.836 QALY; 30% were hospitalized and 14% visited emergency rooms. For all products, costs were approximately 35% due to drugs, 48% hospitalization, and the remainder due to medical care. The analysis was robust against most variations in input values; adherence rates were sensitive. PP-LAI was dominant over OLZ-LAI and RIS-LAI in 50% and 73% of simulations, respectively. CONCLUSIONS: In Finland, PP-LAI dominated the other LAIs as it was associated with a lower cost and better clinical outcomes.